Boehringer Ingelheim pauses Phase 1 study of oral candidate BI 3031185 after safety event

Boehringer Ingelheim has placed a Phase 1 study of its oral candidate BI 3031185 on hold after a safety event was identified.

The trial, run in Japan with healthy volunteers, was assessing tolerability in men and the effect on contraceptive blood levels in women. The company confirmed the pause but provided no further details.

Boehringer said patient safety is paramount and the assessment is ongoing; it will issue an update once the outcome is known. The candidate has already completed two other Phase 1 studies earlier this year.